BioWorld

CCNA2 deficiency impairs endometrial responsiveness to steroids

Cyclins regulate steroid receptor action in cyclin-dependent kinase (CDK)-dependent and independent manners. In addition to regulating the cell cycle, cyclin A2 (CCNA2) also mediates female sex ...
CU Boulder News & Events

MAPK and mTORC1 signaling converge to drive cyclin D1 protein production to enable cell cycle reentry in melanoma persister cells

[button url="http://chem.colorado.edu/" color="blue"]Department of Chemistry and Biochemistry[/button] [button url="www.colorado.edu" color="blue"]University of ...
Business Wire

Circle Pharma Presents Promising Preclinical Data on First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...
Business Wire

Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting

“CID-078 exemplifies Circle Pharma’s commitment to advancing new treatments for patients with cancer,” said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development of Circle Pharma.
ascopubs.org

A phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle.

A phase 1/2 dose escalation study of the oral DNA polymerase theta inhibitor (POLQi) GSK4524101 ± niraparib in adults with advanced or metastatic solid tumors. This is an ASCO Meeting Abstract from ...